Heron Therapeutics Analyst Price Targets - Benzinga

Heron Therapeutics Inc

HRTXNASDAQ

Trade with Public

Trade with Public

$0.3007

-0.0021-0.69%

Últ. Act.: Oct 27, 12:30 AM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

Heron Therapeutics Analyst Price Targets - Benzinga

Heron Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Heron Therapeutics (HRTX).

Price Target Range — 10 Quarters

Analyst Consensus — 4 Analysts

2Buy

2Hold

Consensus RatingOverweight# Analysts4Avg. Consensus PT$7Upside to Avg. PT+2066.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 11, 2026	HC Wainwright & Co.	Brandon Folkes	Downgrade	Buy→Neutral	—
Jun 3, 2026	HC Wainwright & Co.	Brandon Folkes	PT Cut	Buy	$4→$2
Jun 3, 2026	Needham	Serge Belanger	Downgrade	Buy→Hold	—
Jan 9, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$6
Aug 8, 2025	Needham	Serge Belanger	PT Cut	Buy	$4→$3
Jun 9, 2025	HC Wainwright & Co.	Brandon Folkes	Initiate	Buy	$6
Apr 11, 2025	Needham	Serge Belanger	Maintained	Buy	$4
Feb 28, 2025	Needham	Serge Belanger	Maintained	Buy	$4
Dec 4, 2024	Needham	Serge Belanger	Maintained	Buy	$4
Nov 13, 2024	Needham	Serge Belanger	PT Cut	Buy	$5→$4
Sep 25, 2024	Needham	Serge Belanger	Maintained	Buy	$5
Aug 7, 2024	Needham	Serge Belanger	Maintained	Buy	$5
Jun 13, 2024	Rodman & Renshaw	Brandon Folkes	Initiate	Buy	$7
May 16, 2024	Needham	Serge Belanger	Maintained	Buy	$5
May 8, 2024	Needham	Serge Belanger	Maintained	Buy	$5
Apr 23, 2024	Capital One	Tim Chiang	Initiate	Overweight	$6
Apr 11, 2024	Needham	Serge Belanger	Maintained	Buy	$5
Mar 13, 2024	Needham	Serge Belanger	PT Raise	Buy	$4→$5
Nov 15, 2023	Needham	Serge Belanger	PT Cut	Buy	$5→$4

Analyst Ratings News

PRO
HC Wainwright & Co. Downgrades Heron Therapeutics to Neutral

HC Wainwright & Co. analyst Brandon Folkes downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Neutral.

Benzinga Newsdesk

Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday

Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrades, visit analyst ratings page.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Heron Therapeutics, Lowers Price Target to $2

HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $2.

Benzinga Newsdesk

PRO
Needham Downgrades Heron Therapeutics to Hold

Needham analyst Serge Belanger downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Heron Therapeutics, Maintains $6 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $6 price target.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $3

Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $3.

Benzinga Newsdesk